Ziff Davis (ZD) Stock Forecast & Price Target

Ziff Davis is viewed positively because its Q2 results were generally healthy, with revenue of $286.7M, Adj. EBITDA margin of 26.8%, and Adj. EPS of $1.03 all roughly in line to slightly above consensus, while free cash flow beat the Street by about $49.6M. The investment case is further strengthened by management’s disciplined M&A approach, which has historically targeted 2x-3x revenue assets and 20%+ IRRs, alongside proactive strategic alternatives that could unlock shareholder value. Investors also appear to underappreciate the durability of Health & Wellness as the company’s largest profit engine, while the $1.2B connectivity sale and ~$1.6B cash balance enhance financial flexibility for buybacks and future acquisitions.

Ziff Davis is viewed negatively because its downside case assumes weaker growth and margin performance, with valuation compressed to about 2x EV/FCF on 2027 downside-case FCF, implying limited confidence in future cash generation. The company also faces execution risk from acquisitions, including the possibility that future deals may fail or become larger and more expensive as competition for assets intensifies. In addition, its markets are highly competitive—especially media against Google and Facebook—and its healthcare unit carries meaningful regulatory risk, all of which could pressure earnings quality and valuation.